Skip to main navigation Skip to search Skip to main content

Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction

  • David Hasdai
  • , Robert M. Califf
  • , Trevor D. Thompson
  • , Judith S. Hochman
  • , E. Magnus Ohman
  • , Matthias Pfisterer
  • , Eric R. Bates
  • , Alec Vahanian
  • , Paul W. Armstrong
  • , Douglas A. Criger
  • , Eric J. Topol
  • , David R. Holmes*
  • *Corresponding author for this work
  • Rabin Medical Center Israel
  • Duke University
  • Continuum Health Partners, Inc.
  • University of Basel
  • University of Michigan, Ann Arbor
  • Tenon Hospital
  • University of Alberta
  • Cleveland Clinic Foundation
  • Mayo Clinic Rochester, MN

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Abstract

OBJECTIVES: This study characterized clinical factors predictive of cardiogenic shock developing after thrombolytic therapy for acute myocardial infarction (AMI). BACKGROUND: Cardiogenic shock remains a common and ominous complication of AMI. By identifying patients at risk of developing shock, preventive measures may be implemented to avert its development. METHODS: We analyzed baseline variables associated with the development of shock after thrombolytic therapy in the Global Utilization of Streptokinase and Tissue- Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. Using a Cox proportional hazards model, we devised a scoring system predicting the risk of shock. This model was then validated in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) cohort. RESULTS: Shock developed in 1,889 patients a median of 11.6 h after enrollment. The major factors associated with increased adjusted risk of shock were age (χ2 = 285, hazard ratio [95% confidence interval] 1.47 [1.40, 1.53]), systolic blood pressure (χ2 = 280), heart rate (χ2 = 225) and Killip class (χ2 = 161, hazard ratio 1.70 [1.52, 1.90] and 2.95 [2.39, 3.63] for Killip II versus I and Killip III versus I, respectively) upon presentation. Together, these four variables accounted for >85% of the predictive information. These findings were transformed into an algorithm with a validated concordance index of 0.758. Applied to the GUSTO-III cohort, the four variables accounted for >95% of the predictive information, and the validated concordance index was 0.796. CONCLUSIONS: A scoring system accurately predicts the risk of shock after thrombolytic therapy for AMI based primarily on the patient's age and physical examination on presentation.

Original languageEnglish
Pages (from-to)136-143
Number of pages8
JournalJournal of the American College of Cardiology
Volume35
Issue number1
DOIs
StatePublished - Jan 2000
Externally publishedYes

Funding

Funders
Bayer Fund
CIBA-Corning
Sanofi Pharmaceuticals
ICI Pharmaceuticals

    Fingerprint

    Dive into the research topics of 'Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction'. Together they form a unique fingerprint.

    Cite this